Economic evaluation of pharmaco-and behavioral therapies for smoking cessation: A critical and systematic review of empirical research

Annual Review of Public Health

Volumn 33, Issue , 2012, Pages 279-305

  Ruger, Jennifer Prah ^a   Lazar, Christina M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavioral therapy; Cost effectiveness; Cost saving; Economic evaluation; Pharmacotherapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CLONIDINE; DOXEPIN; FLUOXETINE; MOCLOBEMIDE; NALTREXONE; NICOTINE; NICOTINE PATCH; NORTRIPTYLINE; PAROXETINE; RIMONABANT; SELEGILINE; SERTRALINE; VARENICLINE;

ASTHMA; BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; STROKE; SYSTEMATIC REVIEW;

COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DRUG THERAPY; HEALTH CARE COSTS; HUMANS; PUBLIC HEALTH; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84861398576     PISSN: 01637525     EISSN: 15452093     Source Type: Book Series    
DOI: 10.1146/annurev-publhealth-031811-124553     Document Type: Review

References (82)

1. Akers L, Severson HH, Andrews JA, Lichtenstein E. 2007. Cost-effectiveness of self-help smokeless tobacco cessation programs. Nicotine Tob. Res. 9(9):907-14
2. An LC, Schillo BA, Kavanaugh AM, Lachter RB, Luxenberg MG, et al. 2006. Increased reach and effectiveness of a statewide tobacco quitline after the addition of access to free nicotine replacement therapy. Tob. Control 15(4):286-93
3. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. 2009. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin. Drug Investig. 29(10):655-65
4. Antoñanzas F, Portillo F. 2003. Economic evaluation of pharmacotherapies for smoking cessation. Gac. Sanit. 17(5):393-403
5. Assoc. Am. Med. Coll. 2007. Physician Behavior and Practice Patterns Related to Smoking Cessation. Washington, DC: AAMC. http://www.legacyforhealth. org/PDFPublications/Physicians-Study-Legacy-Report.pdf
6. Banta HD, de Wit GA. 2008. Public health services and cost-effectiveness analysis. Annu. Rev. Public Health 29:383-97
7. Barnett PG, Wong W, Hall S. 2008. The cost-effectiveness of a smoking cessation program for outpatients in treatment for depression. Addiction 103(5):834-40
8. Berlin I, Säid S, Spreux-Varoquaux O, Launay JM, Olivares R, et al. 1995. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 58(4):444-52
9. Bolin K, Lindgren B, Willers S. 2006. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest 129(3):651-60
10. Bolin K, Mork AC, Wilson K. 2009. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J. Eval. Clin. Pract. 15(3):478-85
11. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S et al. 2009. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation\results from four European countries. Eur. J. Public Health 19(6):650-54
12. Boyd KA, Briggs AH. 2009. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction 104(2):317-25
13. Brauer CA, Neumann PJ, Rosen AB. 2007. Trends in cost effectiveness analyses in orthopaedic surgery. Clin. Orthop. Relat. Res. 457:42-48
14. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. 2006. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 9:213-18
15. Brownson RC, Fielding JE, Maylahn CM. 2009. Evidence-based public health: a fundamental concept for public health practice. Annu. Rev. Public Health 30:175-201
16. Bryson HM, Milne RJ, Chrisp P. 1992. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics 2(2):118-36
17. Carande-Kulis VG, Maciosek MV, Briss PA, Teutsch SM, Zaza S, Truman BI, et al. 2000. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Am. J. Prev. Med. 18(1 Suppl.):75-91
18. Cent. Dis. Control Prev. 2002. Annual smoking-attributable mortality, years of potential life lost, and economic costs\United States, 1995-1999. MMWR 51(14):300-3. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5114a2.htm
19. Cent. Dis. Control Prev. 2003. Cigarette smoking-attributable morbidity\United States, 2000. MMWR 52(35):842-44. http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5235a4.htm
20. Cent. Dis. Control Prev. 2008. Smoking-attributable mortality, years of potential life lost, and productivity losses\United States, 2000-2004. MMWR 57(45):1226-28. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm
21. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, et al. 2006. Cost-effectiveness ofpharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob. Control 15(3):152-59
22. Crealey GE, McElnay JC, Maguire TA, O'Neill C. 1998. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 14(3):323-33
23. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. 1997. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 278(21):1759-66
24. Cummings SR, Rubin SM, Oster G. 1989. The cost-effectiveness of counseling smokers to quit. JAMA 261(1):75-79
25. Dino G, Horn K, Abdulkadri A, Kalsekar I, Branstetter S. 2008. Cost-effectiveness analysis of the Not On Tobacco program for adolescent smoking cessation. Prev. Sci. 9(1):38-46
26. Drummond MF, Jefferson TO. 1996. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 313:275-83
27. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. 1997. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford Univ. Press
28. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. 1989. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am. J. Psychiatry 146(3):373-76
29. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, et al. 2008. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179(2):135-44
30. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MP. 2005. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 8(3):178-90
31. Fellows JL, Bush T, McAfee T, Dickerson J. 2007. Cost effectiveness of the Oregon quitline "free patch initiative." Tob. Control 16(Suppl. 1):i47-52
32. Fiscella K, Franks P. 1996. Cost-effectiveness of the transdermal nicotine patch as anadjunct tophysicians' smoking cessation counseling. JAMA 275(16):1247-51
33. Folland S, Goodman A, Stano M. 2006. Economics of Health and Health Care. Upper Saddle River, NJ: Prentice Hall. 5th ed.
34. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. 2007. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int. J. Technol. Assess Health Care 23(1):71-79
35. Giacomini M, Miller F, O'Brien BJ. 2003. Economic considerations for health insurance coverage of emerging genetic tests. Commun. Genet. 6:61-73
36. Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F. 2004. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Tob. Control 13(2):190-95
37. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, et al. 1993. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin. Pharmacol. Ther. 54(6):670-79
38. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. 1996. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ. Press
39. Grosse SD, Teutsch SM, Haddix AC. 2007. Lessons from cost-effectiveness research for United States public health policy. Annu. Rev. Public Health 28:365-91
40. Haile MJ, Wiggers JH, Spigelman AD, Knight J, Considine RJ, Moore K. 2002. Novel strategy to stop cigarette smoking by surgical patients: pilot study in a preadmission clinic. ANZ J. Surg. 72(9):618-22
41. Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, et al. 1998. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 55(8):683-90
42. Halpern MT, Dirani R, Schmier JK. 2007. The cost effectiveness of varenicline for smoking cessation. Manag. Care Interface 20(10):18-25
43. Hempel AG, Wagner ML, Maaty MA, Sage JI. 1998. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in Parkinsonian patients with motor fluctuations. Ann. Pharmacother. 32(9):878-83
44. Hilleman DE, Mohiuddin SM, Delcore MG, Lucas BD Jr. 1993. Randomized, controlled trial of trans-dermal clonidine for smoking cessation. Ann. Pharmacother. 27(9):1025-28
45. Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, Riedlinger K. 2007. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tob. Control 16(Suppl 1):i53-59
46. Hoogendoorn M, Welsing P, Rutten-van Mölken MP. 2008. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr. Med. Res. Opin. 24(1):51-61
47. Howard P, Knight C, Boler A, Baker C. 2008. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 26(6):497-511
48. Igarashi A, Takuma H, Fukuda T, Tsutani K. 2009. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics 27(3):247-61
49. Jackson KC 2nd, Nahoopii R, Said Q, Dirani R, Brixner D. 2007. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J. Occup. Environ. Med. 49(4):453-60
50. Jefferson T, Demicheli V, Vale L. 2002. Quality of systematic reviews of economic evaluations in health care. JAMA 287:2809-12
51. Knight C, Howard P, Baker CL, Marton JP. 2010. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health 13(2):209-14
52. Meenan RT, Stevens VJ, Hornbrook MC, La Chance PA, Glasgow RE, et al. 1998. Cost-effectiveness of a hospital-based smoking cessation intervention. Med. Care 36(5):670-78
53. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. 1999. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354:1896-900
54. Mullen PD, Ramirez G. 2006. The promise and pitfalls of systematic reviews. Annu. Rev. Public Health 27:81-102
55. Neumann PJ. 2005. Using Cost-Effectiveness Analysis to Improve Health Care. New York: Oxford
56. Neumann PJ, Fang CH, Cohen JT. 2009. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics 27(10):861-72
57. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. 2005. Growth and quality of the cost-utility literature, 1976-2001. Value Health 8:3-9
58. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. 2000. The quality of reporting in published cost-utility analyses, 1976-1997. Ann. Intern. Med. 132:964-72
59. Oster G, Huse DM, Delea TE, Colditz GA. 1986. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 256(10):1315-18
60. Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, et al. 2007. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am. J. Prev. Med. 33(4):297-305
61. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. 2006. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann. Intern. Med. 145(11):845-56
62. Ruger JP. 2009. Health and Social Justice. Oxford: Clarendon
63. Ruger JP, Emmons KM. 2008. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health 11(2):180-90
64. Ruger JP, Lazar CM. 2012. Economic evaluation of drug abuse treatment and HIV prevention programs in pregnant women: A systematic review. Addict. Behav. 37(1):1-10
65. Ruger JP, Weinstein MC, Hammond SK, Kearney MH, Emmons KM. 2008. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health 11(2):191-98
66. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, Cost Work Group of the Third U.S. Preventive Services Task Force. 2001. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am. J. Prev. Med. 20(3 Suppl.):36-43
67. Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. 2009. Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch. Intern. Med. 169(3):230-35
68. Schroeder SA. 2005. What to do with a patient who smokes. JAMA 294(4):482-87
69. Schroeder SA, Morris CD. 2010. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. Annu. Rev. Public Health 31:297-314
70. Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. 2006. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am. J. Prev. Med. 31(1):62-71
71. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. 2002. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med. Decis. Making 22(5 Suppl.):S26-37
72. Stapleton JA, Lowin A, Russell MA. 1999. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 354(9174):210-15
73. Stone PW, Teutsch SM, Chapman RH, Bell C, Goldie SJ, Neumann PJ. 2000. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am. J. Prev. Med. 19:15-23
74. Thacker SB, Ikeda RM, Gieseker KE, Mendelsohn AB, Saydah SH, et al. 2005. The evidence base for public health: informing policy at the Centers for Disease Control and Prevention. Am. J. Prev. Med. 28:227-33
75. Thavorn K, Chaiyakunapruk N. 2008. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob. Control 17(3):177-82
76. Tran MT, Holdford DA, Kennedy DT, Small RE. 2002. Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy 22(12):1623-31
77. U.S. Dep. Health Hum. Serv. 2008. Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update. Washington, DC: US Dep. Health Hum. Serv. http://www.surgeongeneral.gov/tobacco/treating-tobacco-use08.pdf
78. U. K. Natl. Health Serv. Cent. Rev. Dissem. 2001. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance For Those Carrying Out or Commissioning Reviews. CRD Rep. 4, March. York: Univ. York. 2nd ed. http://www.medepi.net/meta/guidelines/Overview-CRD-Guidelines.pdf
79. Warner KE 1997. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 11(6):538-49
80. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. 1997. The cost-effectiveness of the nicotine trans-dermal patch for smoking cessation. Prev. Med. 26(2):264-70
81. Webb MS, Rodriguez de Ybarra D, Baker EA, Reis IM, Carey MP. 2010. Cognitive-behavioral therapy to promote smoking cessation among African American smokers: a randomized clinical trial. J. Consult. Clin. Psychol. 78(1):24-33
82. World Health Organ. (WHO). 2004. The tobacco atlas. Tobacco Free Initiative. http://www. who.int/tobacco/en/atlas13.pdf